CRNT:NASDAQCeragon Networks Ltd. Analysis
Data as of 2026-06-18 - not real-time
$2.71
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Ceragon Networks (CRNT) is trading at $2.71, which sits below its 20‑day SMA of $2.87 but above the 50‑day ($2.66) and 200‑day ($2.35) averages, indicating a short‑term pullback within a longer‑term bullish backdrop. The RSI of 46 suggests neutral momentum, while the MACD histogram is negative and the signal line is flagged as bearish, reinforcing the near‑term downside pressure. Volume has been trending lower, and the stock is approaching its calculated support at $2.42, with resistance near $3.29.
Fundamentally, the company reports a negative profit margin (-0.7%) and a modest operating margin (3.1%), yet it generates positive free cash flow of $27.5 M and holds more cash than debt. The forward PE of 12.9 is well below the industry average of 37, and a DCF‑derived fair value of $4.08 implies roughly 78 % upside. However, earnings are currently negative (trailing EPS –$0.02) and ROE is -1.4%, highlighting profitability concerns. The high beta (~2.0) and 30‑day volatility of nearly 69 % point to a volatile equity, while the Fear & Greed Index at “Extreme Greed” suggests market optimism may be overstated. Upcoming Q1 results on May 19 could be a catalyst that either validates the upside thesis or confirms the near‑term weakness.
Fundamentally, the company reports a negative profit margin (-0.7%) and a modest operating margin (3.1%), yet it generates positive free cash flow of $27.5 M and holds more cash than debt. The forward PE of 12.9 is well below the industry average of 37, and a DCF‑derived fair value of $4.08 implies roughly 78 % upside. However, earnings are currently negative (trailing EPS –$0.02) and ROE is -1.4%, highlighting profitability concerns. The high beta (~2.0) and 30‑day volatility of nearly 69 % point to a volatile equity, while the Fear & Greed Index at “Extreme Greed” suggests market optimism may be overstated. Upcoming Q1 results on May 19 could be a catalyst that either validates the upside thesis or confirms the near‑term weakness.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and decreasing volume signal near‑term weakness
- Price testing support at $2.42 with limited upside before resistance
- Upcoming earnings release could confirm or reverse the current trend
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value indicates ~78 % upside
- Forward PE far below industry average, suggesting valuation cushion
- Positive free cash flow and cash‑over‑debt position support operational stability
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Long‑term demand for wireless backhaul and 5G infrastructure
- Undervalued relative to peers with solid balance sheet
- Geographic diversification, especially growth potential in India
Key Metrics & Analysis
Financial Health
Revenue Growth-4.10%
Profit Margin-0.73%
P/E Ratio12.9
ROE-1.45%
ROA1.99%
Debt/Equity19.57
P/B Ratio1.4
Op. Cash Flow$35.5M
Free Cash Flow$27.5M
Industry P/E37.0
Technical Analysis
TrendBullish
RSI46.5
Support$2.42
Resistance$3.29
MA 20$2.87
MA 50$2.66
MA 200$2.35
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value$4.08
Target Price$4.83
Upside/Downside78.35%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.05
Volatility68.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.